miRNA-664在宫颈癌患者血浆中的表达及其预后评估价值

摘要

Objective:To investigate the expression of micro ribonucleic acid-664(miRNA-664)in plasma of the patients with cervical cancer and its prognostic value.Methods:The levels of miRNA-664,SCCA and CA125 were detected by RT-PCR in 96 patients with cervical cancer(cervical cancer group),40 patients with CIN(CIN group)and 40 healthy physical examination(control group),and the relation between miRNA-664 expression and clinicopathological features of cervical cancer was analyzed.Kaplan-Meier and COX proportional hazards regression models were used to analyze the effect of miRNA-664 on the prognosis of cervical cancer patients.Results:The lev-els of miRNA-664,SCCA and CA125 in the cervical cancer group were significantly higher than those in the CIN group and the control group[miRNA-664(2 -ΔΔCt):4.73 ± 1.26 vs 1.65 ± 0.51 and 1.20 ± 0.37,SCCA(ng/ml):8.92 ± 2.28 vs 1.95 ± 0.62 and 0.72 ± 0.18,CA125(U/ml):40.85 ± 10.16 vs 15.68 ± 6.40 and 12.65 ± 5.82, all P<0.001].Kaplan-Meier survival analysis showed that progression free survival(PFS)and overall survival time (OS)in patients with high miRNA-664 expression were significantly shorter than those in patients with low miRNA-664 expression.Univariate and multivariate analysis of COX proportional hazards model showed that clinical stage, lymph node metastasis,depth of invasion and high expression of miRNA-664 were independent risk factors for the prognosis of cervical cancer patients[OR(95%CI)=1.853(1. 218 ~2. 735),3.052(2.206 ~4.237),1.416 (1.185~2.208),2.183(1.762~4.064)].Pearson correlation analysis showed that plasma miRNA-664 was posi-tively correlated with SCCA in patients with cervical cancer(P<0.01).Conclusion:Abnormal expression of plasma miRNA-664 is closely related to the clinicopathological features and prognosis of cervical cancer,and is expected to be a potential marker for predicting the prognosis of cervical cancer.%目的:探讨微小核糖核酸-664(miRNA-664)在宫颈癌患者血浆中的表达及其对患者预后的评估价值.方法:采用RT-PCR方法检测96例宫颈癌患者(宫颈癌组)、40例宫颈上皮内瘤变患者(CIN组)和健康体检者(对照组)血浆中miRNA-664、鳞状细胞癌抗原(SCCA)及糖类抗原125(CA125)表达水平,分析miRNA-664表达与宫颈癌临床病理特征的关系.Kaplan-Meier和COX比例风险回归模型分析miRNA-664对宫颈癌患者预后的影响.结果:宫颈癌组血浆miRNA-664、SCCA及CA125表达水平均明显高于CIN组和对照组[miRNA-664(2 -ΔΔCt):4.73 ± 1.26、1.65 ± 0.51和1.20 ± 0.37;SCCA(ng/ml):8.92 ± 2.28、1.95 ± 0.62和0.72 ± 0.18;CA125(U/ml):40.85 ± 10.16、15.68 ± 6.40和12.65 ± 5.82,均P<0.001].Kaplan-Meier生存分析结果显示,miRNA-664高表达患者的无进展生存时间(PFS)和总生存时间(OS)明显短于miRNA-664低表达患者.COX比例风险模型单因素及多因素分析显示,临床分期、淋巴结转移、浸润深度及miRNA-664高表达是影响宫颈癌患者预后的独立危险因素[OR(95%CI)=1.853(1.218 ~2.735)、3.052 (2.206~4.237)、1.416(1.185~2.208)、2.183(1.762 ~4.064)].Pearson相关分析显示,宫颈癌患者血浆miRNA-664与SCCA呈正相关(P<0.01).结论:血浆miRNA-664异常表达与宫颈癌临床病理特征及预后密切相关,有望作为预测宫颈癌预后的潜在标志物.